A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
Public ClinicalTrials.gov record NCT06595238. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Obesity or Overweight With Comorbidity
Study identification
- NCT ID
- NCT06595238
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 262 participants
Conditions and interventions
Conditions
Interventions
- AZD6234 Drug
- Placebo comparator Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2024
- Primary completion
- Dec 2, 2025
- Completion
- Dec 2, 2025
- Last update posted
- Jul 19, 2026
2024 – 2025
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Mobile | Alabama | 36608 | — |
| Research Site | Phoenix | Arizona | 85044 | — |
| Research Site | Long Beach | California | 90815 | — |
| Research Site | Hialeah | Florida | 33012 | — |
| Research Site | Largo | Florida | 33777 | — |
| Research Site | Orlando | Florida | 32825 | — |
| Research Site | Tampa | Florida | 33606 | — |
| Research Site | Woodstock | Georgia | 30189 | — |
| Research Site | Indianapolis | Indiana | 46260 | — |
| Research Site | Lutherville-Timonium | Maryland | 21093 | — |
| Research Site | Gulfport | Mississippi | 39503 | — |
| Research Site | Ridgeland | Mississippi | 39157 | — |
| Research Site | Kansas City | Missouri | 64111 | — |
| Research Site | Omaha | Nebraska | 68134 | — |
| Research Site | Portsmouth | New Hampshire | 03801 | — |
| Research Site | Statesville | North Carolina | 28625 | — |
| Research Site | North Charleston | South Carolina | 29405 | — |
| Research Site | Knoxville | Tennessee | 37938 | — |
| Research Site | Austin | Texas | 78731 | — |
| Research Site | Dallas | Texas | 75230 | — |
| Research Site | Port Arthur | Texas | 77642 | — |
| Research Site | San Antonio | Texas | 78231 | — |
| Research Site | San Antonio | Texas | 78249 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06595238, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06595238 live on ClinicalTrials.gov.